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Abstract
Consensus diagnostic recommendations to distinguish gastro-oesophageal reflux disease (GORD) 
from eosinophilic oesophagitis (EoE) by response to a trial of proton pump inhibitors (PPI) 
unexpectedly uncovered an entity called “PPI-responsive oesophageal eosinophilia” (PPI-REE). 
PPI-REE refers to patients with clinical and histologic features of EoE that remit with PPI 
treatment. Recent and evolving evidence, mostly from adults, shows that PPI-REE and EoE 
patients at baseline are clinically, endoscopically and histologically indistinguishable, and have 
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significant overlap in terms of features of Th2 immune-mediated inflammation and gene 
expression. Furthermore, PPI therapy restores oesophageal mucosal integrity, reduces Th2 
inflammation and reverses the abnormal gene expression signature in PPI-REE patients, similar to 
the effects of topical steroids in EoE patients. Additionally, recent series have reported that EoE 
patients responsive to diet/topical steroids may also achieve remission on PPI therapy. This 
mounting evidence supports the concept that PPI-REE represents a continuum of the same 
immunologic mechanisms that underlie EoE. Accordingly, it seems counterintuitive to 
differentiate PPI-REE from EoE based on a differential response to PPI therapy when their 
phenotypic, molecular, mechanistic, and therapeutic features cannot be reliably distinguished. For 
patients with symptoms and histologic features of EoE, it is reasonable to consider PPI therapy not 
as a diagnostic test, but as a therapeutic agent. Due to its safety profile, ease of administration and 
high response rates (up to 50%), PPI can be considered a first-line treatment, before diet and 
topical steroids. The reasons why some EoE patients respond to PPI, while others do not, remain 
to be elucidated.
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1. HISTORICAL BACKGROUND AND DEFINITIONS
Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GORD) are the 
most prevalent chronic oesophageal inflammatory conditions in children and adults in the 
western world.[1] Whereas the first is an allergen-driven disease, [2] the latter develops as a 
consequence of pathologic exposure of the oesophageal mucosa to acid predominant gastric 
contents.[1] Distinguishing both disorders is important because of their different 
aetiopathogenesis, natural history, and monitoring.[2] However, a rigid distinction between 
EoE and GORD is difficult due to overlapping clinical and histological features, not to 
mention their frequent coexistence and potential partially shared pathogenic pathways.[3] 
The presence of heartburn and marked oesophageal eosinophilia, for instance, might be 
fairly common in both entities.[3,4] In pediatric patients, this differentiation is even more 
complex due to a wider spectrum of clinical manifestations, difficulties in expressing 
symptoms and subtle or absent endoscopic abnormalities.[5]
In order to solve this diagnostic conundrum, the first consensus recommendations for 
diagnosis and management of EoE were published in 2007.[6] These guidelines advocated a 
diagnosis of EoE in patients with symptomatic oesophageal eosinophilia (> 15 eosinophils 
per high power field (eos/HPF)) showing either lack of response to proton pump inhibitor 
(PPI) therapy or a normal acid exposure on oesophageal pH monitoring. Accordingly, a 
diagnosis of GORD was recommended for those patients who were either responders to PPI 
therapy or had objective evidence of pathological oesophageal acid exposure. This 
distinction was based on the assumption that only GORD, as an acid-related disorder, could 
respond to the acid suppressive effect of PPIs. As such, these guidelines equated GORD 
with symptomatic and histological response to PPI therapy. Far from fulfilling the 
expectation of distinguishing GORD from EoE, the recommended PPI trial unexpectedly 
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uncovered a third intriguing category of patients, apparently sharing features of EoE and 
GORD.[4]
Updated consensus recommendations in 2011 [2] included changes to these findings: 1) the 
description of a novel phenotype, PPI-responsive oesophageal eosinophilia (PPI-REE), 
referring to patients with features of EoE who achieve clinical and histological remission on 
PPI therapy 2) response to PPI therapy in patients with PPI-REE was not necessarily 
considered a manifestation of GORD, 3) the retraction of recommending oesophageal pH 
monitoring as a diagnostic criterion, due to its low accuracy to predict response to PPI.[4] 
Nonetheless, support for a PPI trial was maintained as a diagnostic criterion, since PPI-REE 
and EoE were still considered separate clinical entities as they showed a different response 
to the PPI trial.[2]
At this stage, it is crucial to ascertain the accurate location of PPI-REE within the spectrum 
between EoE and GORD, the therapeutic mechanisms leading to responsiveness to PPI 
therapy in patients with suspected EoE and whether the response to a PPI trial has any 
validity as a means of excluding EoE.
2. DIFFERENCES AND SIMILARITIES BETWEEN GORD, PPI-REE AND EOE
The need to distinguish among GORD, EoE and PPI-REE in clinical practice, 
pharmaceutical trials and research studies has led to careful investigations to distinguish 
these entities. The results of these studies are summarized in Table 1.
2.1. Symptoms
In adults, the clinical presentations of GORD and EoE are typically distinct.[3] GORD 
patients present with heartburn, regurgitation and bitter/sour taste of gastric content. 
Dysphagia as a dominant symptom is rare in GORD, unless a peptic stricture is present. 
GORD symptoms are exacerbated after consumption of large meals, rapid eating, acidic 
foods, alcohol, obesity, tobacco, and body position changes. In contrast, EoE adult patients 
present predominantly with intermittent dysphagia during consumption of solid foods, 
commonly associated with food impactions. While heartburn and chest pain may be present 
in EoE, they are characteristically not the dominant complaints reported by adult patients 
and if present, usually accompany dysphagia. Available studies have identified that 
demographics, atopic history and clinical manifestations do not reliably discriminate EoE 
from PPI-REE.[4,7–11] Paediatric presentations of EoE are more heterogeneous and include 
abdominal pain, nausea, reflux-like symptoms not responsive to acid suppression, feeding 
difficulties, and growth failure. It remains unclear if this difference in symptom profile 
reflects inadequate symptom reporting by young children, initial symptoms related to 
inflammation prior to onset of oesophageal remodelling or in part functional symptoms 
caused by comorbid conditions, such as irritable bowel syndrome. Along the same lines, it is 
unclear if adults with EoE only develop dysphagia after an initial period of paediatric type 
symptoms.[5]
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2.2. Endoscopic features
Most GORD patients have a normal appearance to the oesophageal mucosa on endoscopy, 
whereas erosive oesophagitis or Barrett’s oesophagus are identified in the minority.[3] 
Endoscopically, nearly all adult EoE patients demonstrate one or more characteristic 
features of loss of vascular markings, rings, white exudates, longitudinal furrows, narrow 
caliber oesophagus and strictures, whereas some children may have a visually normal 
mucosa.[11,12] Reflecting the natural history of oesophageal remodelling, rings and 
strictures are common in adults but rare findings in children with EoE.[5] Typical EoE 
endoscopic signs are useful in distinguishing GORD from EoE, but not PPI-REE from EoE 
[4,7–8,10–11].
2.3. Histologic findings
Histologic characteristics of GORD include basal cell hyperplasia, papillary elongation, 
dilated intra cellular spaces and a paucity of intraepithelial inflammatory cells. [13] 
Eosinophils may be present in GORD but typically are in low numbers (< 10 eos/hpf), 
although we lack prospective studies defining numbers and extent and numbers of 
eosinophilia observed in GORD. Histologic features of EoE include all of the above GORD 
features with the addition of a marked, eosinophil-predominant, cellular infiltration of the 
mucosa. Superficial squamous epithelial distribution, eosinophil degranulation, eosinophil 
microabscesses and lamina propria fibrosis are also commonly identified in EoE, but not in 
GORD. Mast cells have been recognized in the mucosa of both GERD and EoE patients.
[14,15]. Multiple studies have noted that these histologic features are found in both EoE and 
PPI-REE. These include evidence of superficial distribution of epithelial eosinophils, 
eosinophil degranulation and microabscess formation, [4,7,8,11], basophil infiltration[10] 
and the expression of major basic protein and tryptase.[15] Interestingly, a lower rate of 
response to PPI therapy has been reported in patients with more severe histologic findings 
including either ≥ 15 eos/HPF at 3 levels of biopsies[16] or increasing degrees of 
oesophageal eosinophilia.[4]
2.4. Molecular and genetic features
GORD promotes a pro-inflammatory response characterized by innate immunity with over-
expression of cytokines, such as interleukin (IL)-8 (CXCL8), CCL2 (monocyte 
chemoattractant protein 1 and CCL5 (RANTES) [17]. These cytokines and chemokines 
promote active recruitment of neutrophils and lymphocytes and sometimes a mild 
eosinophilic infiltration, normally < 5–10 eos/HPF. Unlike GORD, EoE is a chronic 
immunoallergic disorder characterized by an aberrant Th2 inflammatory response involving 
IL-5 and IL-13 and local production of CCL26 (eotaxin-3), a chemokine that specifically 
attracts eosinophils to the oesophageal mucosa. When activated, the eosinophils cause local 
tissue damage and recruit and/or activate other effector cells, such as mast cells, which have 
a role in oesophageal fibrotic remodelling. [18] By using whole-genome transcript 
expression profiling of esophageal tissue, a molecular EoE diagnostic panel (EDP) has been 
recently identified.[19] This panel is made of 94 EoE genes and accurately distinguishes 
patients with EoE from GERD or control subjects.[19]
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Over the past years, an increasing number of papers have tried to further characterize PPI-
REE. Baseline markers of eosinophilic inflammation in oesophageal tissue (e.g. eosinophil 
derived major basic protein and CCL26) have been shown to be increased in PPI-REE, 
similar to EoE. In addition, expression of mast cell signature genes (e.g. tryptase) [15], as 
well as expression of genes involved in type 2 (Th2) associated allergic inflammation 
(including CCL26, IL-5, IL-13, thymic stromal lymphopoietin (TSLP) and periostin 
(POSTN) [9,10,20,21] have demonstrated largely overlapping patterns between EoE and 
PPI-REE, although PPI-REE typically has more modest over-expression levels. One of the 
key findings in the past year is that PPI-REE, unlike GORD, has a transcriptome that nearly 
completely overlaps with the EoE transcriptome, including the hallmark EoE genes for 
eosinophil chemotaxis (CCL26), barrier molecules (desmoglein DSG1), tissue remodeling 
(POSTN), and mast cells (CPA3).[22] Overall, these findings suggest PPI-REE and EoE are 
alike and both associated with allergic inflammation (4). In addition, recent clinical studies 
have shown that PPI monotherapy in PPI-REE patients can almost completely reverse the 
Th2 signature of PPI-REE (CCL26, IL-5, IL-13, POSTN) [9,21,22] and concurrently induce 
a normalization of the mast cell genes (CPA3, TPSAB2), Th2 inflammation indicators 
(TNFAIP6, ALOX15), epithelial barrier genes (DSG1, CDH26, FLG), tissue fibrosis markers 
(e.g. KRT13), and IL-13/IL-4–induced genes (POSTN, MUC4) [22]. Since these effects are 
similar to those of topical steroids in EoE patients [9,23], these striking data pose the 
possibility that EoE and PPI-REE represent a common disorder.
Recent genome wide association studies (GWAS) in EoE have identified two replicated 
susceptibility loci at 2p23 and 5q22, regions that encode the epithelial gene products 
CAPN14 and TSLP.[24–26] The presence of susceptibility loci was shown to not depend 
upon response to PPI, reinforcing the idea that esophageal eosinophilia, independent of PPI 
stratification, likely shares genetic etiology.
3. THE EFFICACY OF PPI THERAPY IN PATIENTS WITH SUSPECTED EOE
The evidence for PPIs inducing either clinical or histologic disease remission in patients 
with suspected EoE was initially reported by one case series and three retrospective studies 
published between 2005 and 2009.[16,27–29] The case series reported clinico-histological 
response in all 3 patients, [27] whereas a 50–86% clinical response and a 40% histologic 
response was reported in the retrospective cohorts.[16,28,29] In the first large prospective 
study in adults with clinical, endoscopic and histological features of EoE, an 8 week course 
of PPI therapy led to complete response in 50% of cases.[4] Of note, response to PPI was 
observed in 80% of patients with endoscopic evidence of GORD or abnormal pH 
monitoring, but also in 33% of those with a normal pH study.[4]
Two randomized controlled trials comparing PPIs to topical steroids in patients with an EoE 
phenotype reported a similar efficacy (33%) for PPI therapy.[30,31] The latter trial 
demonstrated a response to PPI in 100% and 18% of patients with a pathological and normal 
pH study, respectively.[31] In three recent prospective studies, 35% to 47% of adult and 
pediatric patients achieved histologic remission (defined by < 5 eos/HPF) on PPI therapy.
[15,32,33] Of note, response to PPI therapy increased up to 50%[30], 57%[32] and 68%[33] 
when histological remission was redefined as < 15 eos/HPF.
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A recent systematic review with meta-analysis, including 33 studies with 619 patients with 
suspected EoE, revealed that PPIs achieved histological remission (defined by < 15 eos/
HPF) in 51% (95% CI, 42.2%–58.7%) and symptomatic improvement in 61% (95%CI, 
48.38% – 72.2%) of cases.[34] No significant differences were noted in patients’ age, study 
design and type of PPI assessed. However, a trend towards increased efficacy was observed 
when PPIs were administered twice daily compared to once daily, and among patients with 
increased oesophageal acid exposure on pH monitoring. Noteworthy, a significant 
publication bias in favor of studies reporting histologic responses to PPI therapy was 
observed in this meta-analysis.
The sustained efficacy of PPIs in children has been evaluated in two retrospective small 
series and a recent prospective study, with most patients (78.6%) remaining in 
clinicopathological remission at one-year follow up while on maintenance PPI therapy.
[33,35–36]. As for adults, the first long-term follow-up multicentre study including 75 PPI-
REE patients demonstrated that the majority of patients (73%) maintained histological 
remission 1 year after tapering dosage to the lowest effective clinical dose.[37] Among 
relapsers, most regained histological remission with dose escalation, suggesting some 
patients with PPI-REE continue to require high-dose maintenance PPI. Allergic 
rhinoconjunctivitis and a CYP2C19 rapid metabolizer genotype predicted long-term relapse, 
hinting at the influence of pharmacogenomic and environmental factors on the long-term 
efficacy of PPI therapy.
4. POTENTIAL MODE OF ACTION OF PPI IN EOE
It is widely appreciated that PPI block gastric acid secretion, and this antisecretory effect is 
assumed to underlie their great efficacy in treating GORD. However, PPI do not prevent the 
reflux of non-acidic material, and up to 20% of GORD patients have symptoms that are 
refractory to PPI. It is less well known that PPI have anti-inflammatory actions (independent 
of antisecretory effects) that also might contribute to healing oesophagitis.[38] PPI have 
anti-oxidant properties, inhibit immune cell functions, decrease adhesion molecule 
expression by endothelial cells, and reduce inflammatory cytokine expression by epithelial 
cells.[39] PPI also have anti-inflammatory effects that might be especially pertinent to the 
allergen-driven eosinophilia of EoE.
In EoE, eosinophils accumulate in the oesophagus when allergens induce production of Th2 
cytokines like IL-4 and IL-13, which stimulate oesophageal secretion of CCL26 (eotaxin-3).
[18] Omeprazole, in concentrations achieved in blood with conventional dosing, inhibits 
Th2 cytokine-stimulated eotaxin-3 secretion in isolated oesophageal epithelial cells by 
blocking binding of the transcription factor STAT6 to the eotaxin-3 promoter.[40,41] 
Lansoprazole exhibits similar actions, suggesting that this inhibition of Th2 cytokine-
stimulated eotaxin-3 secretion is a PPI drug class effect.[41] In one study of children with 
oesophageal eosinophilia, PPI treatment significantly decreased eotaxin-3 protein expression 
by epithelial cells in the proximal but not distal esophagus.[42] In three recent studies 
primarily in adult PPI-REE patients, [9,21,22] PPI reduced oesophageal expression of 
eotaxin-3, IL-5, and mast cell density, suggesting that PPIs down-regulate Th2-mediated 
events. Moreover, gene transcriptome analyses of oesophageal biopsies from adult and 
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pediatric PPI-REE patients have shown a pronounced and specific effect of PPI on reducing 
expression of genes related to allergic inflammation.[22] Impaired oesophageal mucosal 
barrier function, likely mediated by reduced expression of desmoglein-1, is a common 
feature of EoE, and PPIs have been shown to restore mucosal barrier function and improve 
desmoglein-1 expression in patients with PPI-REE.[21,22,43]
All of the therapeutic effects of PPIs on oesophageal inflammation, gene expression and 
mucosal integrity in PPI-REE patients are similar to the responses seen with topical steroid 
therapy in EoE patients.[9,44] Collectively, these data support a trial of PPI for virtually any 
patient with oesophageal eosinophilia, regardless of the underlying mechanism. [45]. If 
eosinophilia is caused solely by GORD and is not antigen-driven, then PPI antisecretory 
effects can improve eosinophilia by limiting acid reflux. If oesophageal eosinophilia is 
solely antigen-driven, anti-inflammatory PPI effects might improve eosinophilia by 
attenuating Th2-associated responses. If GORD causes or exacerbates an antigen-driven 
oesophageal eosinophilia, both the antisecretory and anti-inflammatory effects of PPI might 
combine to ameliorate the condition. Finally, hypersensitivity to acid in the oesophagus has 
been reported in EoE patients.[46] During perfusion of the oesophagus with acid, EoE 
patients felt the burning sensation evoked by the acid earlier than those with concomitant 
reflux or the healthy volunteers.[46] This phenomenon might explain why PPI-mediated 
acid suppression may improve symptoms in some EoE patients, despite the absence of 
histologic remission on PPI therapy.[4,9,16,28,47–49]
5. PPI-REE: IS IT GORD OR IS IT EoE?
The above mentioned data all point in the same direction suggesting that PPI-REE and EoE 
are indistinguishable except that PPI have a more robust effect on PPI-REE patients than 
EoE patients. Subjects with EoE and PPI-REE have similar symptoms, demographics, 
endoscopic findings, histology and response to other treatments besides PPI. Most striking 
perhaps is that the transcriptome of EoE and PPI-REE largely overlaps. Furthermore, recent 
data reveal that EoE patients responsive to diet and topical steroid therapy were eventually 
found to response to PPI therapy as well, providing further data that an allergic 
inflammatory cause is important in PPI-REE.[50,51].
All of these data provide no rational basis to make a distinction between patients with 
symptomatic esophageal eosinophilia based on a different response to PPI therapy. At the 
present time, phenotypic, molecular, mechanistic, and therapeutic features cannot be reliably 
distinguish EoE from PPI-REE. As such, the requirement of a distinct name among 
indistinguishable patients for the sub-group responding to PPI is questionable.[52]. We 
therefore propose not to include the responsiveness to a given drug as a diagnostic criterion 
and, consequently, avoiding the term PPI-REE for those subjects that have an EoE 
phenotype with both histological and clinical response to PPI therapy. Given all of the above 
mentioned arguments, we suggest viewing the PPI trial not as a diagnostic tool for EoE, but 
rather as a potential therapy in all patients with clinical, endoscopical and histological 
features suitable for EoE.
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6. REAPPRAISAL OF THE PPI-TRIAL AS A DIAGNOSTIC TOOL AND 
POSITION OF PPI IN THE TREATMENT OF EOE
Currently, either swallowed topical steroids or dietary elimination are considered 
appropriate first-line therapeutic options after the diagnosis of EoE is established [53,54], 
but these modalities have limitations and neither is universally effective [55,56]. Therefore, 
it is important to consider where PPI might fit in the treatment algorithm for EoE. 
Respecting their favourable safety profile, the simplicity of administration of the compounds 
and high response rates, [34] PPI could be considered as first line therapy for patients with 
EoE. Use of PPI would therefore, instead of deciphering which patients do not have EoE, 
will likely identify a substantial proportion of EoE patients who achieve remission on PPI 
therapy and will not need topical steroid or dietary therapy. As with topical steroid use, it is 
important to note that this represents off-label use of these medications.
7. PROPOSAL FOR UPDATED DIAGNOSTIC CRITERIA FOR EOE
EoE represents a chronic, immune/antigen-mediated oesophageal disease, characterized 
clinically by symptoms related to oesophageal dysfunction and histologically by eosinophil-
predominant inflammation. Eosinophilic inflammation is restricted to the oesophagus and 
other causes of local and systemic oesophageal eosinophilia should be excluded (Table 2).
After a diagnosis of EoE, clinical and histological features of EoE may respond in the 
majority of patients to treatment with PPI, topical steroids or elimination diets.
8. UNSOLVED ISSUES
Can we positively state that PPI-REE is EoE?
No, we cannot. EoE is formally defined as an immune/antigen-mediated disease, but we 
currently lack evidence on the ultimate etiology of PPI-REE. Solid evidence corroborates it 
is a Th2-mediated disease with significant molecular overlap with EoE, but we do not know 
whether this immune response is triggered by reflux-mediated epithelial injury, food/
airborne allergens or the combination of both factors.
In addition, a diagnosis of EoE in patients with no clinical or endoscopic features of EoE 
might be questionable, given the fact we know GORD patients might also have Th1 
mediated oesophageal eosinophilia.[22] However, this subset of patients is likely to 
represent a minority of adult patients. A recent study performed a thorough subanalysis of 
75 PPI-REE patients on long-term follow-up and 86% of patients had typical clinical and 
endoscopic features of EoE, with only one single patient showing a pure GORD phenotype.
[37]. The bulk of evidence on PPI-REE comes from adult patients, so we need further 
prospective studies corroborating these findings in children as well. Based on the high 
population prevalence of GORD, it is inevitable that many patients with EoE will have co-
existing GORD. In such cases or atypical clinical presentations, comprehensive 
consideration of the clinical criteria listed in Table 1, endoscopic features, ambulatory pH 
monitoring, and responsiveness to PPI therapy may have clinical utility in patient 
management.
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Molecular biomarkers distinguishing EoE and PPI-REE would be helpful to distinguish 
between both entities. KCNJ2 has been recently identified as the only gene with significant 
differential expression between PPI-REE and EoE, showing a 72% sensitivity/specificity to 
predict PPI-REE at baseline.[22] KCNJ2 encodes a potassium channel which is abundant in 
gastrointestinal mucosa and colocalizes with the proton pump. Therefore, the authors 
proposed a potential interaction between this potassium channel and proton pump in the 
upper gastrointestinal epithelium to explain PPI-REE. A genome-wide approach currently 
underway may reveal alternative mechanisms that might differentiate the two entities.
Considerations for pediatric patients—A distinction between EoE and GORD may be 
especially complex in children, where EoE symptoms tend to overlap more substantially 
with GORD (feeding difficulties, regurgitation, heartburn) and endoscopic findings are not 
so prototypical as in adults. Concerns about endoscopic procedures in children often lead to 
treatment with PPI before any diagnostic procedures are completed. A symptomatic 
response to PPI will lead to most paediatricians considering a diagnosis of GORD, but a 
diagnosis of PPI-REE might be missed since a biopsy was not obtained. Furthermore, a 
significant dissociation between esophageal symptoms and inflammation has been reported 
in EoE, so a clinical response to PPI therapy does not necessarily rule out EoE.
[4,9,16,28,47–49] Unfortunately, EoE is a clinico-histological entity requiring objective 
confirmation of histological abnormalities for diagnosis and for remission after therapeutic 
interventions.
Performing an additional baseline endoscopy off PPI therapy raises concerns for 
practitioners, parents and patients, but it is critical to remember that normal endoscopic and 
histologic esophageal features on PPI therapy in children with suspected EoE could create a 
lack of diagnostic clarity as well as short and long term therapeutic uncertainty. For 
instance, children with GORD, PPI-REE, functional dyspepsia or recurrent abdominal pain 
might have similar symptoms (regurgitation, vomiting, abdominal pain), experience a 
therapeutic or placebo related response to PPIs and exhibit normal endoscopic and histologic 
features on PPI therapy. Questions of the duration, dose and frequency of PPI treatment will 
remain unanswered. Overall, reconciling concerns about endoscopic procedures and 
anaesthesia with the current need of endoscopy for diagnosis and monitoring EoE will 
continue to be challenging in pediatric patients.
Mechanisms underlying response to PPI therapy—The precise mechanism(s) by 
which PPI accomplish their effects on oesophageal eosinophilia in EoE remains unclear. 
Anti-inflammatory effects of PPIs have been only proven in experimental studies.[40] While 
omeprazole in vitro is present in the culture media for up to 48 hours, the short half-life for 
PPI drugs (1–2 hours active) makes it unclear if a sustained anti-inflammatory effect is 
maintained in vivo. PPI therapy have recently shown their ability to down-regulate Th2 
allergic oesophageal inflammation, [9,21,22] but it is not certain whether this is a direct 
(primary anti-inflammatory effect) or indirect (primary acid inhibition leads to secondary 
inflammation healing) effect.
On the other hand, the role of GORD in PPI-REE is unclear. PPIs can reverse dilation of 
epithelial intercellular spaces and restore mucosal integrity in patients with GORD[57] and 
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PPI-REE[21,43] suggesting reflux may be the initial trigger in some PPI-REE patients. This 
hypothesis might be supported by a greater likelihood of GORD in PPI-REE patients[34]. 
However, the demonstration of pathological oesophageal acid exposure in PPI-REE patients 
does not prove a casual role for GORD, whereas lack of response to PPI does not necessarily 
rule out GORD as a primary trigger for EoE. It will be important to eventually determine if 
PPI-REE patients would also respond to other classes of anti-acid drugs such as Histamine 
Receptor 2 (H2R) antagonists, as it would be informative of the acid-suppressive effects as a 
primary driver of the PPI-REE designation. It is important to acknowledge that no complete 
response of another allergic disease with PPI therapy has been documented so far today.
How do we define response to PPI therapy?—The effect of PPI in patients with 
suspected EoE is not an all or none effect, but a gradient varying between no response, some 
response and near-complete or complete response. It should be emphasized that, currently, a 
diagnosis of EoE which responds to PPI therapy depends on subjective criteria for symptom 
response and on an arbitrary histological cut-off (15 eos/HPF) for histologic response. It is 
likely that PPI use will have at least some effect in most patients, suggesting that either the 
acid inhibitory and/or the anti-inflammatory effect of PPI may play a smaller or larger role 
in these patients.
Adequate doses, dosing interval and duration of PPI therapy—It is also 
necessary to determine the dose and duration of an adequate initial PPI trial. An 8 week 
course of any of the available agents at a regular dose twice daily (pantoprazole 40 mg, 
rabeprazole 20 mg, lansoprazole 30 mg; all BID) or double dose once daily (omeprazole 40 
mg, esomeprazole 40 mg) has been proposed as sufficient to assess a response to PPI 
therapy [2]. In young children, dosing should be weight-based as appropriate. However, 
evidence supporting the recommendations is poor and conflicting.[34] While there does not 
seem to be a relation between the medication dose and response rate in prospective studies, 
it is clear that any of the PPI agents can be effective when used at a “high daily dose” (Table 
3). The first meta-analysis on this issue has recently suggested a non-statistically significant 
advantage of a twice daily administration, with no differences between drugs or doses [34]. 
Future prospective dose-ranging studies of PPIs in patients with esophageal eosinophilia 
would be helpful in providing more definitive dose and duration recommendations.
Natural history and long-term prognosis of responders to PPI therapy—The 
similarities between PPI-REE and EoE also raise the question of whether both disorders 
share a comparable pathogenesis and whether, if left unmanaged, PPI-REE can lead to 
reversal of oesophageal fibrosis. [58] Further studies should address this issue.
Combination therapy: PPI plus steroid/diet therapy—Another area of speculated 
use is in combined therapy with steroids, particularly for refractory patients. This would 
combine PPIs impeding antigen penetration of the esophageal mucosa through epithelial 
repair and steroids blunting the allergy based anti-inflammatory response. There is also data 
that PPIs inhibit different cytokines in EoE and GORD when compared to steroids, thus 
potentially and synergistically enhancing an anti-inflammatory response.[59]
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Table 1
Updated similarities and differences between GORD, PPI-REE and EoE
GORD PPI-REE EoE
Age Adults > Children Children and young adults Children and young adults
Gender Male = Female Male predominance Male predominance
Dominant symptom Heartburn, regurgitation Dysphagia Dysphagia
Food impaction Uncommon Common Common
Endoscopic findings Normal endoscopy (70–80%)
Erosions, ulcers, strictures, 
Barrett’s oesophagus, 
oesophageal adenocarcinoma
Normal endoscopy (<10%)
Oedema, rings, exudates furrows, 
strictures, crêpe-paper 
oesophagus, narrow caliber 
oesophagus
Normal endoscopy (<10%)
Oedema, rings, exudates. 
furrows, strictures, crêpe-paper 
oesophagus, narrow caliber 
oesophagus
Histology and Inflammatory 
cells
Usually < 5–10 eos/HPF
Neutrophils, lymphocytes, low-
grade eosinophilia
> 15 eos/HPF
Eosinophils and mast cells
> 15 eos/HPF
Eosinophils and mast cells
Oesophageal acid exposure on 
pH monitoring
Mostly positive Positive and negative Negative and positive
Primary treatment Inhibitors of gastric acid 
secretion, including PPI, 
surgical fundoplication
PPI therapy, unclear whether 
other inhibitors of gastric acid 
secretion are effective
Topical steroids
Elimination diet
Aetiology Reflux of gastric contents Unclear Food/airborne allergens
Type of immune response/ 
involved chemo/cytokines
Th1
IL-8, MCP-1, RANTES
Th2
Eotaxin-3, IL-5, IL-13
Th2
Eotaxin-3, IL-5, IL-13
EoE transcriptome panel Not expressed Similar expression to EoE Similar expression to PPI-REE
Specific molecular effect of 
therapy
- PPI downregulate Th2 
inflammation and normalize EoE 
gene expression
Topical steroids downregulate 
Th2 inflammation and normalize 
EoE gene expression
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Table 2
Proposal for Updated Diagnostic Criteria for EoE.
1 Symptoms of oesophageal dysfunction (dysphagia/food impaction in adults; abdominal pain, nausea, reflux-like symptoms, 
feeding difficulties, growth failure, dysphagia in children)
2 Baseline oesophageal eosinophil-predominant inflammation (characteristically consisting of a peak value of ≥ 15 eos/HPF) 
limited to the oesophagus.
• Baseline endoscopy should be preferably performed off PPI therapy to better understand the patient profile in case of further 
response to PPI therapy.
• Other local and systemic causes of esophageal eosinophilia should be ruled out: eosinophilic gastroenteritis, Crohn’s disease, 
hypereosinophilic syndrome, parasites, drug hypersensitivity, achalasia, vasculitis, pemphigoid, connective tissue disorders, graft-
versus-host disease.
• Biopsies from the antrum and/or duodenum should be obtained in all children and in adults with gastrointestinal symptoms or 
endoscopic abnormalities
• A diagnosis of EoE in patients based solely on histology, without clinical and endoscopic features compatible with EoE, might be 
questionable
• Routine oesophageal pH monitoring is not recommended in the diagnostic work-up of EoE.
• A majority of EoE patients will achieve symptom response and histological remission (< 15 eos/HPF) on PPI, topical steroid or 
dietary intervention
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Table 3
PPI doses and duration and response rates in prospective studies evaluating PPI-REE.
First author, year of publication Drug, doses Dosing interval Duration Histological remission rates 
after PPI therapy (definition)
Peterson KA, 2010[30] Esomeprazole 40 mg Once daily 8 weeks 33% (< 5 eos/HPF)
50% (< 15 eos/HPF)
Molina-Infante J, 2011[4] Rabeprazole 20 mg Twice daily 8 weeks 50% (< 15 eos/HPF)
Francis DL, 2012[46] Esomeprazole 40 mg Twice daily 6 weeks 61% (average < 5 eos/HPF)
Moawad FJ, 2013[31] Esomeprazole 40 mg Once daily 8 weeks 33% (< 7 eos/HPF)
Dellon ES, 2013[7] Any of the PPI drugs at 20–40 mg Twice daily 8 weeks 36% (< 15 eos/HPF)
Vazquez-Elizondo G, 2013[32] Omeprazole 20 mg Twice daily 8 weeks 25% (< 5 eos/HPF)
56% (< 15 eos/HPF)
Molina-Infante J, 2014[9] Omeprazole 40 mg Twice daily 8 weeks 43% (< 15 eos/HPF)
Van Rhijn BD, 2014[21] Esomeprazole 40 mg Twice daily 8 weeks 50% (< 15 eos/HPF)
Gutiérrez-Junquera C, 2015 [33] Esomeprazole 1 mg/kg/dose Twice daily 8 weeks 47% (< 5 eos/HPF)
68.6% (< 15 eos/HPF)
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